Central banks may need to increase quantitative easing programs according to an analysis from JPMorgan Chase & Co. The investment firm’s report resonates with the conclusion by Goldman Sachs Group strategists of limiting bond yields.
The expected increase of this year’s $2.1 trillion supply could offset the $1.9 trillion demand to $200 billion, the JPMorgan team said, implying an upward pressure on yields. Strategists from Goldman Sachs said that an increasing issuance would lead to higher rates and steeper curves.
Policy makers have aimed to force down yields in sovereign markets as governments spend trillions in a bid to put a floor under an economy severely affected by the COVID-19 pandemic.
Despite an upsurge in demand for bonds, JPMorgan reported that appetite could dwindle in 2020 for commercial banks, pension funds and insurance companies, and foreign-exchange reserve managers.
The U.S. Federal Reserve, European Central Bank, Bank of Japan, and the Bank of England will make certain that demand will expand by $4.2 trillion this year. However, commercial lenders will see a decline in demand to around $1 trillion, according to the report.
The self-driving car company Waymo LLC and Fiat Chrysler Automobiles NV (FCHA.MI) signed a partnership deal on Wednesday to fully develop self-driving cars, pickups, and SUVs. Waymo, an Alphabet Inc. (GOOGL.O) unit, and Fiat Chrysler said ...
The Securities and Exchange Commission (SEC) announced on Monday that UBS Financial Services Inc. (UBSG) would pay more than $10 Million to resolve charges regarding certain municipal bond offerings. UBS has agreed to pay the fine after SEC ...
Oil prices steadied on Tuesday, stuck in narrow ranges as investors pinned hopes on fuel demand recovery amid renewed lockdowns due to rising coronavirus cases. Prices were supported by positive news on vaccine development as medical institutions ...
On Monday, U.S. international banking giant Goldman Sachs (G.S.) said that it would resume negotiations with the Malaysian government this week to hammer out a multi-billion dollar financial settlement lost in a scandal at sovereign fund 1Malaysian ...
Glenmark Pharmaceuticals Ltd was given a notice by the Drug Controller General of India (DCGI) on overpricing and false claims of its generic version of favipiravir, FabiFlu, according to local media reports, sending the company’s ...